Eli lilly and company (LLY)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09
Cash Flows from Operating Activities
Net Income (Loss) Attributable to Parent

5,533

8,318

7,947

7,843

6,256

3,232

450

-143

1,124

-204

2,224

2,447

2,186

2,737

2,444

2,465

2,319

2,408

2,358

2,059

2,192

2,390

2,689

3,392

3,864

4,684

4,784

4,908

4,625

4,088

4,119

4,029

4,302

4,347

4,659

4,725

4,877

5,069

4,815

4,454

4,263

4,328

0

0

0

Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Gain (Loss) on Disposition of Business

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

1,149

1,232

1,237

1,364

1,542

1,609

1,675

1,632

1,603

1,567

1,500

1,519

1,498

1,496

1,495

1,460

1,455

1,427

1,423

1,407

1,387

1,379

1,390

1,397

1,412

1,445

1,439

1,459

1,457

1,462

1,436

1,425

1,418

1,373

1,393

1,379

1,369

1,328

1,365

2,555

1,903

1,297

0

0

0

Change in deferred income taxes

-146

-62

-141

-180

-277

-326

778

948

939

787

-240

-903

-598

-439

1,068

1,583

886

748

-859

-824

-213

-36

-921

-343

-144

-265

475

-77

-44

-126

696

433

228

268

-301

-257

-421

-559

-976

-847

-549

-189

0

0

0

Stock-based compensation expense

308

312

303

296

287

279

278

280

280

281

275

267

262

255

246

240

230

217

200

183

166

156

155

153

148

144

146

144

145

141

137

139

140

147

166

177

195

231

279

657

508

368

0

0

0

Acquired in-process research and development (Note 3)

155

239

569

517

2,116

1,980

1,697

1,876

252

1,110

1,092

887

887

30

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development, net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

252

252

252

252

32

91

91

91

58

0

0

0

Income related to termination of the exenatide collaboration with Amylin

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

495

495

1,283

1,283

787

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from (payments for) terminations of interest rate swaps

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

97

-161

-141

-340

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other changes in operating assets and liabilities, net of acquisitions and divestitures

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Net marketing investigation charges accrued paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-307

-1,313

0

0

0

Other non-cash operating activities, net

306

348

306

370

418

472

396

486

459

441

443

277

133

376

282

192

558

263

610

590

219

280

-92

-24

27

25

178

215

205

187

125

-13

-18

-17

-117

-97

-131

-178

598

310

316

362

0

0

0

Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Net Cash Provided by Operating Activities

4,907

4,836

4,321

4,933

5,399

5,524

5,819

5,578

5,712

5,615

5,878

5,659

5,410

4,851

3,840

3,283

2,830

2,964

3,409

3,996

4,101

4,458

4,744

5,044

5,627

5,735

5,610

5,162

4,831

5,304

5,647

6,176

6,910

7,234

7,517

7,203

7,074

6,856

6,647

6,193

5,205

4,335

0

0

0

Cash Flows from Investing Activities
Net purchases of property and equipment

1,088

1,033

1,101

1,108

1,177

1,210

1,259

1,232

1,144

1,076

1,043

1,027

1,051

1,037

1,007

1,053

1,031

1,066

1,094

1,118

1,149

1,162

1,217

1,174

1,056

1,012

961

889

932

905

748

741

701

672

667

655

670

694

700

710

733

765

0

0

0

Cash released for pending acquisition (Note 3)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,405

0

0

0

5,405

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sales and maturities of short-term investments

137

136

133

145

2,137

2,552

5,067

5,671

4,134

4,852

2,716

2,394

2,288

1,642

1,821

1,801

2,176

2,161

2,978

3,449

3,394

4,054

3,603

3,227

2,879

3,320

2,799

3,144

3,084

2,547

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of short-term investments

9

42

34

34

33

112

528

1,618

3,212

3,389

3,875

2,945

1,518

1,327

503

519

774

842

1,000

1,421

1,400

1,637

2,154

1,819

1,620

1,531

1,082

1,911

1,872

2,172

4,472

3,354

3,210

2,058

-59

164

146

686

364

61

-112

-399

0

0

0

Proceeds from sales of noncurrent investments

580

609

563

530

3,282

3,509

4,343

4,873

2,368

2,586

2,166

2,274

2,275

2,086

2,403

2,237

2,811

3,068

5,925

7,219

8,972

11,009

10,107

11,311

11,770

11,235

9,281

7,367

5,030

4,355

4,613

4,154

3,349

2,138

1,222

637

605

584

810

1,123

1,114

1,107

0

0

0

Purchases of noncurrent investments

269

247

314

308

336

837

1,591

2,929

4,227

4,611

4,444

4,435

4,575

4,346

4,193

3,662

3,018

3,226

3,839

6,040

7,956

9,802

12,439

13,160

14,950

14,041

12,351

10,618

7,323

7,618

7,306

6,299

6,377

4,459

3,208

2,451

1,248

1,067

621

561

421

432

0

0

0

Proceeds from sale of product rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

410

410

410

410

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of product rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

36

70

105

138

129

268

636

632

629

475

472

442

0

0

0

-

-

-

-

Purchases of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-241

-161

95

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-140

-140

-140

-90

0

0

0

Cash paid for acquisitions, net of cash acquired (Note 3)

849

6,917

6,917

6,917

6,917

0

0

0

0

882

882

882

927

45

40

51

6

5,283

5,287

5,276

5,828

551

0

0

0

-

-

-

-

199

199

507

503

307

0

0

0

-

-

-

-

-

-

-

-

Purchases of in-process research and development

135

319

549

501

2,004

1,807

1,628

1,803

255

1,086

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other investing activities, net

-188

248

479

481

552

187

185

103

188

175

233

215

101

130

106

103

167

133

-231

-16

-9

24

364

144

115

97

-34

-52

-63

-64

140

124

95

112

172

193

243

219

103

112

86

94

0

0

0

Net Cash Used for Investing Activities

-1,465

-8,082

-8,700

-8,674

-5,602

1,906

4,217

2,858

-2,524

-3,783

-6,614

-5,651

-4,423

-3,139

-1,707

-1,482

-279

26

-2,405

-3,485

-4,136

-3,909

-2,962

-2,256

-3,039

-2,072

-2,502

-1,691

-825

-2,832

-3,047

-3,922

-5,436

-4,824

-4,512

-4,292

-3,147

-3,159

-1,849

-993

-137

142

0

0

0

Cash Flows from Financing Activities
Dividends paid

2,443

2,409

2,395

2,380

2,361

2,311

2,287

2,262

2,232

2,192

2,184

2,175

2,167

2,158

2,150

2,139

2,137

2,127

2,119

2,117

2,105

2,101

2,104

2,107

2,113

2,120

2,140

2,156

2,173

2,187

2,183

2,179

2,181

2,180

2,180

2,184

2,169

2,165

2,160

2,152

2,154

2,152

0

0

0

Net change in short-term borrowings

893

995

-3,436

-384

855

-2,197

2,467

1,023

-302

1,397

2,521

1,420

1,791

1,293

-1

-2

-593

-2,680

-305

-1

592

2,680

0

0

0

-

-

-

-

0

-112

-12

-23

-134

-28

-2

16

125

-869

-1,012

-1,588

-5,824

0

0

0

Proceeds from issuance of long-term debt

2,108

6,556

4,448

6,926

6,926

2,477

0

0

0

-

-

-

-

-

-

-

-

4,454

4,454

4,454

2,182

992

992

992

992

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

2,400

0

0

0

Repayments of long-term debt

2,542

2,866

607

607

808

1,009

1,001

1,001

800

630

630

630

630

0

0

0

0

-

-

-

-

1,034

1,041

1,042

1,011

10

5

4

4

1,511

1,515

1,515

1,514

61

55

56

55

1

0

0

0

-

-

-

-

Purchases of common stock

1,400

4,400

5,200

5,600

6,550

4,150

3,150

2,150

1,399

299

499

499

300

600

553

614

739

749

796

1,035

1,055

800

1,000

700

555

1,698

1,919

1,919

1,919

721

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Other financing activities, net

-200

-200

-253

-337

-390

-372

-378

-347

-345

-364

-368

-377

-411

-300

-312

-255

-181

-52

14

136

146

96

109

-8

-6

0

0

0

0

-

-

-

-

6

-3

21

19

19

0

0

0

-

-

-

-

Net Cash Provided by Financing Activities

-3,585

-2,324

-2,850

-725

-670

-5,904

-4,807

-4,739

-2,848

142

1,070

-30

-511

-559

-1,816

-1,811

-3,334

-3,111

-702

-513

-272

-166

-2,739

-2,863

-2,694

-3,829

-4,058

-4,073

-4,092

-4,419

-3,805

-3,701

-3,713

-2,369

-2,268

-2,221

-2,188

-2,021

-2,600

-3,120

-3,700

-5,533

0

0

0

Effect of exchange rate changes on cash and cash equivalents

-194

-89

-166

-60

-174

-63

6

50

127

-20

-98

-145

-166

-236

-66

-66

25

-85

-228

-447

-515

-341

-244

54

57

-21

0

43

-99

43

-73

-320

-146

-110

-48

260

42

-144

-136

-239

43

21

0

0

0

Net decrease in cash and cash equivalents

-337

-5,660

-7,396

-4,527

-1,047

1,462

5,235

3,747

467

1,954

235

-168

309

915

250

-77

-757

-205

73

-450

-823

41

-1,203

-20

-48

-188

-950

-559

-185

-1,903

-1,278

-1,767

-2,384

-70

688

950

1,781

1,530

2,060

1,841

1,412

-1,033

0

0

0